论文部分内容阅读
德国拜耳集团(Bayer)宣布,计划在未来完全专注于生命科学业务——医药保健和作物科学,旗下拜耳材料科技业务单元将被剥离,并进入股票市场。据公司介绍,拜耳将创建两家全球顶级的企业:生命科学领域的世界级创新公司——拜耳;以及聚合物领域的领先公司——材料科技。生命科学业务目前已经占到拜耳集团销售总额的大约70%以及EBITDA(息税折旧摊销前利润)的88%,而材料科技业务计划在未来的12~18个月内完成剥离,使其进入股票市场。近年来,拜耳集
Germany’s Bayer Group announced plans to fully focus on the life sciences business - healthcare and crop science - in the future with its Bayer MaterialScience business unit to be spun off and into the stock market. According to the company, Bayer will create two of the world’s top companies: a world-class innovation company in the life sciences sector - Bayer; and a leader in polymer technology - materials technology. The life sciences business now accounts for about 70% of the Bayer Group’s total sales and 88% of EBITDA (EBITDA), while the Materials Technology business plans to complete the divestiture in 12 to 18 months in the future Stock market. In recent years, Bayer set